Using MRI to predict Crohn's disease relapse after stopping biologics
Official title: MR Enterography Predictors of Disease Relapse After Stopping Biologic Therapy in Crohn's Disease (METEOR).
Run by University College, London · NCT06124287 · Data updated 2026-11-12
This study is testing if MRI scans can help predict when people with Crohn's disease might have a relapse after stopping their medication.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 16 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University College, London Academic / other |
| Drugs / interventions | Adalimumab, infliximab, Certolizumab, Ustekinumab, Natalizumab, Vedolizumab |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | February 27, 2024 |
| Main results expected | August 2026 |
| Study ends | February 2027 |
| Registry record updated | May 13, 2024 |
| Trial ID | NCT06124287 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 16 and older with luminal small bowel or colonic Crohn's disease in clinical remission who have recently undergone MRE as part of routine care.
✕Probably not a fit
Patients who have stopped biologic therapy for reasons other than clinical remission or those under 16 years of age may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the effectiveness of MR Enterography (MRE) in predicting relapse in Crohn's disease patients who have stopped biologic medication while in clinical remission. By analyzing MRI scans and collecting clinical data from up to 200 patients across NHS hospitals, the study aims to identify predictors of early relapse, including blood and stool tests. The goal is to develop a statistical model that incorporates MRE scores to enhance the prediction of relapse risk within one year. The findings could contribute to a clinical decision support tool for better patient management.
Why it matters
Potential benefit: If successful, this study could help identify Crohn's disease patients at high risk of relapse, allowing for more personalized treatment plans.
How similar studies have gone: Other studies have explored the use of imaging techniques in predicting disease outcomes, but this specific approach using MRE for Crohn's disease relapse prediction is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Luminal small bowel or colonic Crohn's disease in clinical remission * 16 years or older * MRE as part of routine care performed within three months prior, or one month after the decision to stop biologic therapy Anti-TNF (Adalimumab, infliximab, Certolizumab) IL-23 or IL-12 antagonists (Ustekinumab) Anti-integrin biologics (Natalizumab, Vedolizumab) * Biologic therapy stopped due to clinical remission only Definition of clinical remission: There is no agreed consensus on how clinical remission is defined and practice differs between hospitals and patients. To mirror current clinical practice, no strict definition of clinical remission will therefore be used. Detailed clinical parameters the time of stopping biologic agents will be collected. Exclusion Criteria: \<16 years of age Non-biological therapy, unless part of combination therapy with biologic agents Biological therapy stopped for other reasons e.g. loss of effect, side effects Resection of diseased segment(s) after MRE but before stopping biologic agent. No MRE with the time window defined by eligibility criteria
Where it's running
-
University College London Hospital
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Maira Hameed — University College London Centre for Medical Imaging
- Study coordinator: Maira Hameed
- Email: maira.hameed@ucl.ac.uk
- Phone: 020 7679 9274
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Iron treatment for children and young adults with Crohn’s disease and iron deficiency anemia
This study tests how different iron treatment approaches work for kids and young adults with Crohn’s disease and iron deficiency anemia.
-
Autologous intestinal organoids applied to Crohn's ulcers in a first-in-human dose-escalation study
This early-phase study tests a patient-derived intestinal organoid therapy (ATORM-C) delivered during colonoscopy to Crohn’s ulcers to see if it is safe and tolerable and to get a sense of healing.
-
SL-325 in Crohn's Disease: a phase 2 test for adults with moderate to severe disease
This phase 2 study tests SL-325 against placebo in adults with moderately to severely active Crohn's disease to see if it helps improve symptoms and disease activity.
-
Advanced therapies for moderately to severely active Crohn's disease or ulcerative colitis in adults
This study tests combinations of risankizumab with either trosunilimab or ABBV-701 in adults with moderately to severely active Crohn's disease or ulcerative colitis.
-
Stop PPI in active IBD: can you safely go without acid-suppressing meds?
This study tests whether people with inflammatory bowel disease who have been on proton pump inhibitors can stop taking them and still manage their symptoms.
-
Tabellvi for moderate to severe Crohn's disease in Chinese adults
This real-world, single-arm study tests Tabellvi® (adalimumab) in Chinese adults with moderate to severe Crohn's disease to see how often side effects occur and whether many patients reach remission by week 26.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.